Publications by authors named "S Percin"
Article Synopsis
- Tumor-infiltrating memory T cell subpopulations in non-small cell lung cancer (NSCLC) can be categorized based on various surface markers, with CD103 often used but not universally expressed.
- In studies, multiparametric cytometry and multiplex immunofluorescence techniques were applied to analyze T-cell behavior in vaccinated mice and human NSCLC patients, revealing distinct subpopulations and their impact on clinical outcomes.
- Results showed that a specific double-positive T cell subset (CD103+CD49a+) was more functional than a single-positive subset (CD49a+), with implications for predicting responses to immunotherapy, particularly relating to PD-1 treatment.
Background: The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression in the first-line setting is important to optimize postprogression treatments. We evaluated the efficacy of FST in patients from PAOLA-1/ENGOT-ov25 (NCT02477644) who received first-line olaparib maintenance.
View Article and Find Full Text PDFIntroduction: The low incidence and heterogeneity of sarcomas limit understanding of their progression in metastatic cases. The use of metastasectomy is debated due to lack of consensus and evidence-based data. This study aimed to identify simple prognostic factors that could contribute to the therapeutic strategy.
View Article and Find Full Text PDFDe novo germline pathogenic variants (gPV) of the BReast CAncer 1 (BRCA1) gene are very rare. Only a few have been described up to date, usually in patients with a history of ovarian or breast cancer. Here, we report the first case of an incidental de novo BRCA1 germline pathogenic variant which was identified within the framework of the Plan France Médecine Génomique (PFMG) 2025 French national tumor sequencing program.
View Article and Find Full Text PDFArticle Synopsis
- * Two pharmacokinetic/pharmacodynamic models were created using patient data to understand how olaparib affects hemoglobin and creatinine levels over time, leading to the identification of a target concentration for monitoring treatment.
- * The models effectively tracked changes in blood parameters for patients, concluding that a plasma concentration of 3500-4000 ng/mL is linked to a significant risk of severe anemia in over 20% of patients.